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Abstract
For female patients with rheumatoid arthritis, the availability of a
host of new disease modifying antirheumatic drugs has raised
important questions about fetal safety if a woman becomes
pregnant while she is being treated. In addition, there is limited
safety information regarding many of the older medications
commonly used to treat rheumatoid arthritis in women of
reproductive age. Current summary pregnancy risk information for
selected medications used to treat rheumatoid arthritis is reviewed
in the context of the pregnancy label category. In addition, the
strengths and weaknesses of post-marketing strategies for
developing new pregnancy safety information are described.
Introduction
For female patients with rheumatoid arthritis (RA), the
availability of a host of new disease modifying antirheumatic
drugs (DMARDs) has raised important questions about fetal
safety if a woman becomes pregnant while she is being
treated. In addition, there is limited safety information
regarding many of the older medications commonly used to
treat RA in women of reproductive age.
Although pre-marketing clinical trials and post-marketing
safety studies can address questions regarding safety in
most segments of the population, pregnant women constitute
one special group for whom ethical concerns prohibit the
establishment of human drug safety information as part of the
drug development and approval process. However, once a
new drug is marketed or an existing drug is used for a new
indication, if women of reproductive age are prescribed the
drug, pregnancy exposures will inevitably occur. This is due
to the fact that about half of pregnancies in the US are
unplanned [1], and overall fewer than 50% of women
recognize they are pregnant by the fourth week in gestation
[2], leading to the common occurrence of inadvertent
exposure to a medication of unknown safety during a critical
period in embryonic development.
Thus, the rheumatologist and the pregnant patient are
frequently faced with the dilemma of assessing the potential
risk of an exposure to a medication or combination of
medications that has already occurred early in pregnancy, or
of making the decision to continue or discontinue a
medication regimen during a planned pregnancy or
breastfeeding.
In the US, the resource that clinicians and patients rely on
most heavily in evaluating individual risk is the US Food and
Drug Administration’s (FDA) Pregnancy Category: A, B, C, D,
X [3]. Pregnancy safety cannot be ethically evaluated in pre-
marketing human clinical trials. In the post-marketing setting,
isolated case reports of adverse pregnancy outcomes are
difficult to interpret without a known denominator of exposed
women, and post-marketing controlled observational studies
are not systematically conducted. Therefore, there are
insufficient human pregnancy safety data available for more
than 80% of drugs currently available on the US market [4].
Thus, as shown in Table 1, the pregnancy category is a
designation that is almost exclusively derived from preclinical
animal reproductive and developmental toxicity studies. This
is despite the fact that animal studies are not always
predictive of human pregnancy risk. Drugs that have been
identified as teratogenic in selected animal species may have
been tested at doses that far exceed the normal human
therapeutic  range. Furthermore, even at comparable doses,
medications shown to be teratogenic in one or more animal
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species may not produce the same results in humans or any
adverse effects at all. Conversely, drugs that have demon-
strated no adverse effects in selected animal species may in
fact be human teratogens [5]. Therefore, until adequate human
pregnancy safety data are available, the pregnancy category
designation has limited value in predicting safety or risk.
The purpose of this paper is two-fold. First, we present
current summary pregnancy risk information for selected
medications or classes of medications used to treat RA. This
information is intended to describe both the substantial gaps
in current knowledge as well as the frequent discordance
between the FDA Pregnancy Category and currently available
data. Secondly, we compare the strengths and weaknesses
of post-marketing strategies for developing new pregnancy
safety information, with a specific focus on pregnancy
registries using the Organization of Teratology Information
Specialists (OTIS) Autoimmune Diseases in Pregnancy
Project design for illustration.
Review of pregnancy safety information
A brief review of the literature and pregnancy exposure risk
assessment for selected agents used to treat RA is
presented below. In addition, in Tables 2 through 4, a
summary risk statement in comparison with the FDA
Pregnancy Category is listed for each agent or selected
agents within a class.
Anti-inflammatory agents
Corticosteroids
An association between prenatal exposure to corticosteroids,
such as prednisone, and intrauterine growth restriction in
humans has long been recognized. The risk appears to be
dose related, suggesting that this concern can be minimized
with lower doses [6-8]. Although cortisone is known to cause
cleft palate in rats and mice, until recently no such
association has been suspected in humans [9]. However,
among four recent case-control studies and a meta-analysis,
three studies and the meta-analysis conclude that systemic
corticosteroid use in the period surrounding the time of
conception appears to be associated with a three- to six-fold
increased risk for cleft lip with or without cleft palate and
possibly cleft palate alone. It is unclear to what extent this
association is explained by the various underlying maternal
diseases involved in these studies or other unmeasured
confounders [10-14]. To put these relative risks into
perspective, in that the population birth prevalence of all oral
clefts combined is approximately 1 per 1,000 live births,
systemic corticosteroid use is associated with a risk of either
cleft lip with or without cleft palate or cleft palate alone of
approximately 1.3 to 3.3 for every 1,000 pregnancies
exposed during the critical period for lip/palate closure.
Based on these data, it is suggested that the risk associated
with prenatal exposure to these medications is minimal.
Non-steroidal anti-inflammatory drugs
The non-steroidal anti-inflammatory drugs (NSAIDs) include
celecoxib, indomethacin, ibuprofen, sulindac, ketoprofen,
diclofenac, meloxicam, ketorolac, naproxen, nimesulide and
piroxicam.
A number of studies in which pregnancy outcome has been
documented in the offspring of women treated during early
pregnancy with various NSAIDs have been published
[15-24]. Based on those studies, in general it is not thought
that NSAIDs are serious teratogens but may be associated
with low risks for certain congenital malformations and
possibly miscarriage.
Three case-control studies have examined the association
between ibuprofen and gastroschisis, a rare defect that
occurs normally in about 1 in 10,000 live births. These
studies have produced conflicting results. One study demon-
strated a four-fold increased risk when mothers reported
Table 1
FDA pregnancy categories
Category Description
A Adequate and well-controlled studies have failed to demonstrate a risk to the fetus in the first trimester of pregnancy (and there is 
no evidence of risk in later trimesters)
B Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in 
pregnant women
C Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in 
humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks
D There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or 
studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks
X Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on 
adverse reaction data from investigational or marketing experience, and the risk involved in use of the drug in pregnant women 
clearly outweighs potential benefitsPage 3 of 10
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using ibuprofen in the three month period around the time of
conception, while the other two studies showed no such
association [19-21]. It is important to recognize that although
one study has raised the possibility of increased risk,
gastroschisis is so uncommon that the potential absolute risk
is extremely low. In addition, one large Swedish cohort study
has shown an approximate two-fold increased risk for cardiac
defects with any NSAID use in early pregnancy and an
approximate three-fold increased risk for oral clefts with early
pregnancy use of NSAIDs, specifically naproxen [16]. A
second case-control study using the same data source also
showed an approximately two-fold increased risk for cardiac
defects in association with early pregnancy use of naproxen
[22]. In contrast, in a Danish study of NSAID use in early
pregnancy, no increased risk for malformations, preterm
delivery or low birth weight was noted [23]. However, this
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Table 2
Anti-inflammatory medications
FDA 
pregnancy  Adverse effects in 
Class Agent category human pregnancy Summary risk assessment
Corticosteroids Prednisone  C  Oral clefts increased risk (two- to  Based on available data, teratogenic risk for 
Cortisone  D  three-fold). Intrauterine growth  corticosteroids is minimal
All others C restriction (dose related)
NSAIDs Celecoxib  C Ibuprofen associated with increased  Significant risk for premature closure of the 
Diclofenac  C risk (two- to three-fold) for  ductus arteriosus and other complications 
Ketorolac  C gastroschisis. NSAIDs associated  when exposure occurs in late pregnancy; 
Prixicam  C with increased risk for spontaneous  minimal or undetermined risk for structural 
All others  B abortion; possible increased risk for  defects following first trimester exposure
cardiac defects; premature closure 
All NSAIDs in  D of the ductus arteriosus with third 
third trimester trimester use
NSAIDs, non-steroidal anti-inflammatory drugs.
Table 3
Disease-modifying antirheumatic drugs
FDA 
pregnancy 
Agent category Adverse effects in human pregnancy Summary risk assessment
Methotrexate X Pattern of malformation, including apparent  Based on available data, contraindicated in 
dose-related abnormalities of growth, craniofacies,  human pregnancy; unknown magnitude of risk
limb development, and neurodevelopment
Sulfasalazine B Possible increased risk for malformations  Based on limited data, a substantial teratogenic 
suggested in two studies; other studies negative risk is unlikely
Leflunomide X No documented increased risk for structural  Based on minimal data in human pregnancy, 
defects in humans teratogenic risk is undetermined
Hydroxychloroquine C No documented increased risks for malformations;  Although data are insufficient, a substantial 
theoretical concerns for retinal toxicity and  teratogenic risk is unlikely
ototoxicity, but no reported cases
Azathioprine D No documented increased risk for structural  Although data are limited, a substantial risk for 
defects; growth and gestational age effects may  structural malformations is unlikely
be related to transplant status
Cyclosporine  C No documented increased risk for structural  Based on limited data, risk for structural 
defects; growth and gestational age effects may  malformations is unlikely
be related to transplant status
Chlorambucil D Case reports only - two with unilateral renal  Based on insufficient data, teratogenic risk is 
agenesis undetermined
Cyclophosphamide D Pattern of malformation including increased  Based on available data, contraindicated in 
risk for abnormalities of growth, craniofacies,  human pregnancy; unknown magnitude of risk
limb development, and neurodevelopmentstudy and one additional US study have both shown an
increased risk for spontaneous abortion (two- to seven-fold)
when NSAIDs are used early in pregnancy [23,24]. At
present, these data do not provide sufficient or conclusive
evidence that early pregnancy use of any NSAID, including
naproxen, causes heart defects or oral clefts, even at a low
level of risk. Two studies show an increased risk for
spontaneous abortion, although it is unclear to what extent
the indication for use of the medication may have contributed
to pregnancy loss.
Despite the demonstrated lack of substantial teratogenic risk
following first trimester exposure to NSAIDs, a number of
risks have been documented when fetal exposure occurs late
in pregnancy. Premature closure of the fetal ductus arteriosus
with resultant pulmonary hypertension has been noted in
association with third trimester use of NSAIDs [25]. Renal
dysgenesis leading to oligohydramnios has been reported
following later pregnancy exposure to indomethacin,
ibuprofen, naproxen, ketoprofen, nimesulide, and piroxicam
[26]. Necrotizing enterocolitis and ileal perforation as well as
intraventricular hemorrhage and cystic brain lesions have
been seen in preterm infants exposed to indomethacin prior
to delivery [27,28]. These complications are thought to be
related to the extent to which the individual NSAID selectively
inhibits cyclooxygenase (COX)1 as opposed to COX2.
Based on studies in rats and rabbits, compounds that
selectively inhibit COX1 or have a high ratio of COX1/COX2
inhibition are more likely to be associated with the induction
of developmental defects [29].
The extent of the ductal constriction, and possibly the other
neonatal complications listed above, are gestational-age
dependent. Although in utero ductal constriction seldom
occurs with prenatal exposure earlier than 27 weeks’
gestation, a significant risk is present at or beyond 32 weeks’
gestation, leading to the recommendation that NSAIDs be
discontinued prior to that gestational age. In cases in which
that approach is followed, neonatal complications in full term
babies are rare.
Disease modifying antirheumatic drugs
Methotrexate
Both aminopterin and its methyl derivative, methotrexate, have
been associated with a specific pattern of malformation in
infants born to mothers who use one of these medications early
in pregnancy. The principal features of this pattern, referred to
as the aminopterin/methotrexate syndrome, include prenatal
onset growth deficiency, severe lack of calvarial ossification,
hypoplastic supraorbital ridges, small low set ears, micro-
gnathia, limb abnormalities, and in some cases developmental
delay [30-31]. The majority of affected infants have been born
to women treated with high dose methotrexate for psoriasis,
neoplastic disease and/or as an abortafacient [32].
Pregnancy outcomes in 23 women with RA who had 25
pregnancies treated with methotrexate have been reported
[32-35]. The dosage of methotrexate in these pregnancies
was low, ranging from 7.5 to 12.5 mg/week. Nine of the 25
pregnancies resulted in spontaneous abortions and 14
resulted in normal babies. One woman who received a total
methotrexate dose of about 100 mg over the first 8 weeks of
her pregnancy had a baby with the aminopterin/methotrexate
syndrome, and two women electively terminated their
pregnancies. In another case series, pregnancy outcome was
reported for 28 women, 22 of whom were treated for RA, and
all but one whose doses were <15 mg/week during early
pregnancy. Five pregnancies ended in elective termination,
four in spontaneous abortion and the remaining 19 resulted in
live births. One child presented with mild neonatal
abnormalities consisting of bilateral metatarsus varus and
right eyelid angioma [36]. Based on these cases, it has been
suggested that the maternal methotrexate dose necessary to
produce the aminopterin/methotrexate syndrome is greater
than 10 mg/week [32]. Furthermore, it has been suggested
that the critical period of exposure relative to the risk for the
syndrome is between six and eight weeks post-conception
[32]. However, data are still insufficient to verify the exact
threshold dose, the critical window of exposure, or the
magnitude of the risk for the syndrome following first trimester
exposure to methotrexate.
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Table 4
Disease modifying anti-rheumatic drugs: biologics
FDA 
pregnancy 
Agent category Adverse effects in human pregnancy Summary risk assessment
Etanercept  B No documented increased risk for structural  Based on minimal data in human pregnancy, 
Infliximab  B defects teratogenic risk is undetermined
Adalimumab B
Rituximab C No documented increased risk for structural  Based on lack of data in human pregnancy, 
defects based on case report teratogenic risk is undetermined
Anakinra B No available human data Based on lack of data in human pregnancy, 
teratogenic risk is undeterminedThe concomitant use of folic acid supplements to protect
against the deleterious effects of prenatal methotrexate
exposure has not been evaluated. However, a recent study
suggests that the folic acid component of multivitamins may
reduce the risk of neural tube defects, oral clefts, cardio-
vascular defects, and urinary tract defects in the offspring of
women taking other folic acid antagonists including
trimethoprim, triamterine and sulfasalazine [37].
Sulfasalazine
Three observational studies have been conducted including
the offspring of more than 300 women with inflammatory
bowel disease treated with sulfasalazine during pregnancy
[38-40]. No indication of an association between structural
defects and prenatal exposure to sulfasalazine is evident
based on those studies. However, in two recent case-control
studies, both using the same dataset, an approximate two- to
three-fold increased risk for neural tube defects, cardio-
vascular defects and oral clefts was documented following
early pregnancy exposure to one of a group of folic acid
antagonist medications. Sulfasalazine was one of the
medications classified in this group [37,41]. Of particular
significance, the adverse effects of this group of medications
were diminished by the use of multivitamin supplements
containing folic acid. Numbers of exposed women were
insufficient in either of these studies to calculate a risk
specifically for sulfasalazine [37,41]. In another study, which
was survey based, an overall increased risk for congenital
anomalies with prenatal sulfasalazine exposure was sugges-
ted [42]. However, another population-based case control
study found no such association [43]. Published case reports
have documented five children with structural defects born to
four women treated during pregnancy with sulfasalazine.
These include two children with a ventricular septal defect
and aortic coarctation [44,45], one child with cleft lip/palate
and hydrocephalus [45], and a stillborn twin pair, one with
left-sided renal agenesis and a rudimentary left uterine cornu
and the other with bilateral renal agenesis [46].
Although no large well-controlled studies of sulfasalazine used
for the treatment of RA have been published, based on the
available data, even if there is a risk associated with
sulfasalazine, it is likely to be very low. However, because of the
potential risk associated with folic acid antagonist medications,
when sulfasalazine is prescribed to a women of childbearing
potential, the routine recommendation to take folic acid
containing vitamin supplements is especially important.
Leflunomide
The largest series of peer-reviewed published data available
regarding the prenatal effects of leflunomide in humans is
from a questionnaire mailed to rheumatologists regarding
their practices when prescribing DMARDs [47]. In this
summary of retrospectively reported pregnancies with no
comparison group, there were no malformations reported
among the offspring of 10 women who were prescribed
leflunomide during pregnancy. An additional three case
reports of women with first trimester exposure to leflunomide
were reported by an Italian Teratology Information Service.
Two of these pregnancies ended in voluntary termination and
the third in a normal live birth [48]. Another 43 pregnancy
outcomes with first-trimester exposure to leflunomide have
been published in abstract [49]. In an ongoing prospective
controlled study of RA medications in pregnancy being
conducted by the North American Organization of Teratology
Information Specialists, 43 leflunomide-exposed women were
compared to 78 women with RA who did not use leflunomide
and a second group of 47 women without RA. Based on very
small numbers, rates of major birth defects were similar
between the groups. Infants exposed to leflunomide were
significantly more likely than non-diseased comparison infants
to be born prematurely and were significantly smaller in birth
weight. However, there were no significant differences on
these two measures between the leflunomide-exposed group
and the RA comparison group, suggesting that the underlying
disease and/or other medications used to treat RA are likely
related to these adverse outcomes.
Despite the minimal data in humans, leflunomide has been
assigned an FDA pregnancy category X. This is based on its
mechanism of action (interference with DNA and RNA
synthesis) [50], as well as animal studies in pregnant rats and
rabbits that demonstrated an increased risk for congenital
malformations in their offspring [51]. However, based on a
lack of adequate data in human pregnancy, at the present
time, the teratogenic risk of leflunomide is unknown.
Hydroxychloroquine
Much of the literature regarding antimalarials is based on the
prenatal effects of the drug chloroquine used in relatively low
doses (300 mg/week) for malaria prophylaxis [52-54]. In
these studies, no increased risk for structural abnormalities or
pregnancy loss was documented following first trimester
exposure. Relative to the use of antimalarial drugs for the
treatment of rheumatic diseases, additional studies have
been required because of the higher doses used for
treatment of those disorders. However, no increased risk for
congenital malformations has been documented following
first trimester exposure to hydroxychloroquine for the
treatment of connective tissue disorders in several small
studies [55-57]. Furthermore, in a controlled study of 133
women with connective tissue disorder, no increased
incidence of adverse pregnancy outcomes was noted [58].
Increased risks for spontaneous abortion and preterm
delivery have been reported in studies of chloroquine and
hydroxychloroquine used primarily for the treatment of lupus,
but both of these adverse outcomes may be related to the
maternal underlying disease [59-62].
Based upon the retinal toxicity and ototoxicity of chloroquine
both in animals and humans [63,64], theoretical concerns for
these effects with hydroxychloroquine have been raised.
Available online http://arthritis-research.com/content/8/4/215
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impairment associated with prenatal hydroxychloroquine have
appeared in the literature, and in the limited number of
children who have been systematically evaluated, opthal-
malogical examinations have been normal [55,58]
In summary, the prenatal effects of high dose hydroxy-
chloroquine used for the treatment of RA have not been
studied adequately. However, the available data on the use of
hydroxychloroquine for other rheumatic diseases is not
suggestive of an increased risk.
Azathioprine
Most of the data on the effects of azathioprine on fetal
development have come from studies of its use for prevention
of transplant rejection [65-69]. However, reports of
approximately 190 babies born to women treated with
azathioprine for inflammatory bowel disease or lupus have
been published [70-74]. No increased risk for structural
defects has been documented in any of these studies,
although sample sizes are only sufficient to rule out large risks
for any specific major birth defect. An increased frequency of
prematurity and intrauterine growth restriction following
prenatal exposure to azathioprine has been noted in the
offspring of women with renal transplants; however, it is
possible that the mother’s transplant status itself is a
contributory factor [65-69]. Similarly, it is difficult to separate
the possible effects of the drug from the underlying maternal
disease in attributing the increased risk for fetal death noted
in one study in association with maternal azathioprine
treatment for systemic lupus erthythematosus [71].
Cyclosporine
A substantial amount of data regarding the prenatal effects of
cyclosporine, used in combination with other drugs for the
prevention of transplant rejection, has been published
[75-78]. An increased risk for structural defects has not been
documented in these studies. Of the 16 children who had
defects, no consistent pattern of malformations was
documented. The increased incidence of prematurity and
intrauterine growth restriction that has been consistently
noted in these studies is possibly attributable to the maternal
transplant status. Furthermore, a meta-analysis of studies
evaluating outcomes for a combined sample of 410
pregnancies with prenatal exposure to cyclosporine did not
produce statistically significantly increased risks for major
malformations, preterm delivery or low birth weight relative to
controls [79]. Recognized toxicities of cyclosporine include
nephrotoxicity and hypertension. Recent animal studies have
suggested that prenatal exposure to cyclosporine was
associated with long-term systemic and renal effects that
were not noted in the newborn period [80]. At the present
time, it is suggested that a substantial risk for malformations
following prenatal exposure to cyclosporine is unlikely.
However, long-term effects in humans prenatally exposed to
this drug require further evaluation [81].
Other agents: chlorambucil and cyclophosphamide
Although rarely used in the treatment of RA, pregnancy
outcome has been reported in four women treated with
chlorambucil. Unilateral renal agenesis was reported in two of
the four [82-83]. No epidemiological study regarding human
pregnancy outcome has been published, although these
findings are consistent with the animal data [84]. These data
are insufficient to substantiate teratogenic risk; however, if such
a risk exists, the magnitude of the risk in humans is unknown.
Similarly, cyclophosphamide is uncommonly used in the
treatment of RA, except in patients who have systemic lupus
erythromatosus. Eight case reports documenting a unique
pattern of malformation in infants prenatally exposed to
cyclophosphamide have been published [85]. The principle
features of this disorder, referred to as the cyclophosphamide
embryopathy, are similar to those seen following prenatal
exposure to methotrexate and include growth deficiency,
craniofacial anomalies, and absent fingers and toes. Among
the three case reports in which infants survived and for which
developmental information was available, significant delays
were noted in all. An additional five case reports of
cyclophosphamide use to treat lupus have been reported in
the literature. Two pregnancies with first-trimester exposure
ended in spontaneous abortion, two with second trimester
exposure ended in fetal demise, and one with treatment
initiated in the second trimester ended with a normal live born
infant [86,87]. Although no epidemiological studies of
prenatal exposure to cyclophosphamide have been
published, the similar pattern of malformation seen in case
reports suggests that cyclophosphamide is a human
teratogen, although the magnitude of risk is unknown.
Tumor necrosis factor inhibitors: biologics etanercept,
infliximab, adalimumab
Minimal human pregnancy information has been published for
any of these medications, and the majority of data consists of
isolated case reports, retrospective surveys and otherwise
uncontrolled studies.
No malformations were reported in the offspring of 14 women
who were prescribed etanercept during pregnancy and
whose rheumatologists responded retrospectively to a mailed
survey [47]. Another single case report of normal pregnancy
outcome in a woman with RA and infertility who received
chronic therapy with etanercept has been reported in the
literature [88]. From an ongoing prospective controlled study
of RA medications in pregnancy being conducted by the
North American Organization of Teratology Information
Specialists, 32 pregnancy outcomes following etanercept
exposure and 4 following infliximab exposure have been
reported in abstract. Based on very small numbers, there was
no excess of major birth defects in comparison to the two
control groups. However, similar to the findings with
leflunomide from this same study, etanercept or infliximab-
exposed infants were more likely to be born prematurely and
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not have RA, but were similar in gestational age and birth
weight to unexposed infants whose mothers did have RA.
These preliminary findings suggest that the maternal
underlying disease or factors other than exposure to tumor
necrosis factor inhibitors were involved [89].
Two other studies involving pregnancy outcome in women
receiving infliximab have been published. The first of these
involves analysis of 58 spontaneous reports of 1st trimester
exposed pregnancies either retrospectively or prospectively
reported to the drug manufacturer with no comparison group
[90]. The majority of women were being treated for Crohn’s
disease. Although it is not possible from the published data to
determine the exact percentage of women who had live births
as opposed to spontaneous abortions or elective termina-
tions, the authors conclude that the data did not suggest an
increased risk for pregnancy loss. Of the five live born infants
in this series who had complications, two were structurally
normal but had complicated neonatal courses and three had
structural or developmental problems. One member of a twin
pair was developmentally delayed, one child had Tetralogy of
Fallot and one had intestinal malrotation. In a second study
based on a retrospective chart review with no comparison
group, the offspring of 10 women who received infliximab
treatment throughout pregnancy for Crohn’s disease were
evaluated [91]. All 10 were live born infants without structural
anomalies or intrauterine growth restriction; however, 3 of the
10 were born prematurely.
One case report of a woman treated with adalimumab through-
out pregnancy for Crohn’s disease has been published, and
this pregnancy resulted in a normal full-term infant [92].
One additional abstract summarized the results of an on-line
survey of rheumatologists. Of 463 pregnancies identified by
rheumatologists, detailed data were gathered on 95
pregnancies, 84 of which were determined to have been
exposed to a tumor necrosis factor inhibitor. Of those cases,
81% were exposed to etanercept, 12% to infliximab, and 9%
to adalimumab [93]. Outcomes as reported by rheuma-
tologists for the entire group of exposed women were similar
to expected rates in the general population, although there
was no formal control group. At present there is insufficient
information to draw conclusions about the safety of these
medications during human pregnancy, but the available data
have not raised concerns.
Other biologics: rituximab and anakinra
Two case reports have been published describing women
with non-Hodgkins lymphoma who were treated with
rituximab and both of whom were reported to have normal
babies [94,95]. To date no published information is available
on the use of anakinra in pregnancy. Therefore, information is
insufficient to evaluate the safety of these medications in
pregnancy.
Discussion
As indicated by this review, there is a general lack of
adequately powered and well-designed studies regarding
pregnancy safety for the majority of medications frequently
used by women with RA during pregnancy. Furthermore, as
highlighted in Tables 2 through 4, there are apparent
inconsistencies between the FDA Pregnancy Category and
the risk assessment reflective of the human data for a number
of these medications. For example, although there is
extremely sparse or no human data for all six of the newer
DMARDs, including leflunomide and the new biologics,
pregnancy categories for medications in this group include B,
C and X. Similarly, for azathioprine, chlorambucil and cyclo-
phosphamide, the teratogenic risk based on the available
human data ranges from ‘unlikely’, ‘undetermined’ to ‘contra-
indicated’ during pregnancy, and yet all three of these
medications carry an FDA Pregnancy Category D. These
discrepancies are critically important for the rheumatologist
and the pregnant patient as the FDA category is frequently
relied upon as the primary determinant of whether or not a
medication is safe to use in pregnancy.
In addition to the lack of sufficient quantity of human data for
most medications, the quality of human data that is available
is limited. Retrospective adverse event or case reports lack
denominator information and cannot demonstrate an excess
risk over baseline; survey data often suffer from poor response
rates, which can threaten the validity of conclusions;
uncontrolled studies with no attention to potential
confounding, including confounding by maternal disease, are
difficult to interpret; and information on outcomes is often
incomplete without comprehensive data on the range of
outcomes, including malformations, fetal growth and preterm
delivery.
Yet, the demand for this information is urgent, particularly
when a new drug is marketed and likely to be used by women
of reproductive age. As a result, pregnancy registries have
become increasingly utilized as a post-marketing tool for
collecting pregnancy safety information as quickly as possible
for a new drug or for a previously marketed drug that is being
used for a new indication.
The common elements of ‘traditional’ pregnancy registry
designs include enrollment on the basis of a pregnancy
exposure to a specific target medication, collection of
pregnancy exposure and outcome information (either retro-
spectively or prospectively, most commonly collected from
health care providers, and outcomes usually restricted to
major birth defects), and comparison of those outcomes to
expected numbers (usually general population rates for major
birth defects).
The ‘traditional’ design of pregnancy registries has led to a
number of epidemiological concerns about the validity of
conclusions that can be drawn from such studies. In
Available online http://arthritis-research.com/content/8/4/215
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and Research (CDER) published guidelines for the conduct
of pregnancy registries aimed at setting uniform standards for
these kinds of observational studies [96]. As specified in that
document, issues related to study validity include prospective
recruitment of a sufficient sample size of exposed pregnant
women (i.e., while still pregnant and before prenatal
diagnosis), adequate detail and accuracy in exposure and
outcome information, an appropriate comparison group, and
minimal lost-to-follow-up.
Each of these issues presents significant challenges in the
real world. One approach to meeting these challenges is
that developed by OTIS, a North American network of
telephone information services based in universities,
hospitals and departments of health at 18 sites throughout
the US and Canada. OTIS member services provide risk
counseling to approximately 100,000 pregnant women and
health care providers per year regarding pregnancy and
breastfeeding exposures. At the same time, OTIS services
collaborate to conduct pregnancy outcome studies for
selected exposures [97]. One such study is the OTIS
Autoimmune Diseases in Pregnancy Project, first initiated in
its present form in 2004 [98].
This project represents a new effort involving the
collaboration of OTIS member services, rheumatologists,
pharmaceutical company sponsors, and pregnant women
who are interested in contributing to better knowledge about
the safety of medications used to treat RA. A prospective
cohort study design is used with women recruited on the
basis of having a diagnosis of RA, regardless of the
medications used to treat the disease. In addition, pregnant
women are recruited who do not have RA but have contacted
an OTIS member service with questions about other
exposures not deemed to be teratogenic. Recruitment is
accomplished through referrals of spontaneous callers to
OTIS member services, direct referrals through rheuma-
tologists and other health care providers, and self-referral of
women through the internet or other promotional methods.
Unique features of the OTIS study design include the
following. First, the study objectives are not limited to
evaluation of the safety of a single drug but rather to the
evaluation of the wide variety of medications that are used to
treat a specific disease during pregnancy. Second, the
objectives of the study are not limited to estimation of the risk
of major birth defects, but rather include a more comprehen-
sive evaluation of the spectrum of adverse pregnancy
outcomes, including spontaneous abortion, reduced birth
size, preterm delivery, and postnatal growth deficiency. Third,
the evaluation of each infant for birth defects is performed by
one of a team of specialists who use a standard checklist to
examine each child for any structural abnormalities, including
both major and minor birth defects. Fourth, rather than
comparing outcomes to a national population standard, the
OTIS study employs disease-matched and non-diseased
comparison groups recruited through the same referral
mechanisms used to recruit exposed women. This allows for
more appropriate comparisons regarding medications used
specifically to treat RA, while at the same time controlling for
the underlying disease and disease severity. Fifth, a
commitment to completion of the study is made by the
pregnant woman herself, so that complete outcome
information is typically collected on 95% or more of all
subjects. And sixth, enrollment of the pregnant woman herself
allows for repeated and comprehensive collection of
pregnancy exposure timing and dose information, including
over-the-counter drugs, and information on potential
confounding variables such as alcohol and tobacco use. This
type of detailed information is usually not reliably available
from secondary sources such as medical records or health
care provider reports.
In addition, the OTIS Autoimmune Diseases in Pregnancy
Project offers an immediate benefit to research participants
as the OTIS project staff are available to provide individual
counseling regarding any and all exposures that may have
occurred during pregnancy.
Conclusion
The availability of several new medications available to the
rheumatologist for the treatment of patients with RA has
dramatically changed the short and long-term prognosis for
these patients. However, at the same time, little is known
about the prenatal effects of these medications. In addition,
despite the length of time many of the older drugs have been
marketed, limited data are available regarding their repro-
ductive or developmental toxicity, particularly when used for
the treatment of RA. Although the FDA pregnancy categories
have provided some guidance for rheumatologists treating
pregnant women as well as women in their reproductive
years, the lack of knowledge about the effects of these drugs
in human pregnancy makes these categories ineffective when
counseling women regarding their reproductive risks.
Through increasing awareness, it is hoped issues relating to
reproductive toxicity will become a critical component of our
public health agenda.
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